Fentanyl Transdermal Recalled

February 21, 2025

The information on this site is not intended to take the place of your doctor or other healthcare professionals. It is a resource to help you make the best decisions and get the most from the medical services available to you. A licensed physician should be consulted for diagnosis and treatment of all medical conditions.

On Jan. 31, 2025, Alvogen, Inc. issued a recall for one lot to the consumer level for Fentanyl Transdermal System 25 mcg/h transdermal patches. The patches are packaged in a single product pouch where they can be adhered to one another or multi-stacked. There is a risk of too high of a dose than what is intended, resulting in respiratory depression or death. Fentanyl is a potent opioid used for the management of severe or persistent pain in patients who have a tolerance for opioids and require extended daily use or in which alternative pain treatment options are not adequate. Patients with affected patches should immediately remove them and contact their healthcare prescriber. Additionally, they should return unused patches to the dispensing pharmacy. For additional information see, here.

Last updated: February 21, 2025

The information on this site is not intended to take the place of your doctor or other healthcare professionals. It is a resource to help you make the best decisions and get the most from the medical services available to you. A licensed physician should be consulted for diagnosis and treatment of all medical conditions.